Exact Sciences Corporation (EXAS) Financials

NASDAQ:EXAS

Market Cap

13.66B

Total Revenue

2.08B

Gross Profit

1.51B

Operating Income

-577.54M

Net Income

-623.51M

Metric	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
revenue	4,144,000	1,798,000	39,437,000	99,376,000	265,989,000	454,462,000	876,293,000	1,491,391,000	1,767,087,000	2,084,279,000
costOfRevenue	--	4,325,000	24,501,000	45,195,000	79,196,000	117,982,000	216,717,000	354,324,000	458,757,000	574,394,000
grossProfit	4,144,000	-2,527,000	14,936,000	54,181,000	186,793,000	336,480,000	659,576,000	1,137,067,000	1,308,330,000	1,509,885,000
researchAndDevelopmentExpenses	27,678,000	28,669,000	33,914,000	33,473,000	42,139,000	68,210,000	139,694,000	554,052,000	385,646,000	393,418,000
sellingAndMarketingExpenses	9,578,000	38,908,000	82,140,000	112,826,000	153,924,000	249,448,000	385,176,000	589,919,000	861,889,000	846,011,000
generalAndAdministrativeExpenses	13,649,000	30,435,000	57,950,000	76,898,000	109,040,000	178,293,000	352,453,000	481,716,000	801,262,000	737,304,000
sellingGeneralAndAdministrativeExpenses	23,227,000	69,343,000	140,090,000	189,724,000	262,964,000	427,741,000	737,629,000	1,071,635,000	1,663,151,000	1,583,315,000
operatingExpenses	50,905,000	98,012,000	174,004,000	223,197,000	305,103,000	495,951,000	893,358,000	1,695,420,000	2,143,798,000	2,087,427,000
operatingIncome	-46,761,000	-100,539,000	-159,068,000	-169,016,000	-118,310,000	-159,471,000	-233,782,000	-558,353,000	-835,468,000	-577,542,000
totalOtherIncomeExpensesNet	316,000	542,000	1,271,000	2,018,000	3,932,000	21,203,000	-35,069,000	-298,752,000	-7,038,000	-55,028,000
ebitda	-46,445,000	-100,539,000	-159,068,000	-169,016,000	-118,310,000	-159,471,000	-217,747,000	-464,955,000	-740,467,000	-480,092,000
depreciationAndAmortization	1,418,000	3,710,000	7,750,000	11,509,000	15,555,000	23,084,000	16,035,000	93,398,000	95,001,000	97,450,000
interestIncome	316,000	--	--	--	--	--	--	--	--	--
interestExpense	69,000	51,000	6,000	213,000	206,000	36,789,000	61,599,000	95,983,000	18,606,000	19,634,000
incomeBeforeTax	-46,514,000	-100,048,000	-157,803,000	-167,211,000	-114,584,000	-175,057,000	-268,851,000	-857,105,000	-842,506,000	-632,570,000
incomeTaxExpense	-1,033,000	-3,659,000	-7,744,000	-11,296,000	-187,000	92,000	-184,858,000	-8,572,000	-246,881,000	-9,064,000
netIncome	-46,514,000	-100,048,000	-157,803,000	-167,211,000	-114,397,000	-175,149,000	-83,993,000	-848,533,000	-595,625,000	-623,506,000
eps	-0.69	-1.25	-1.71	-1.63	-0.99	-1.43	-0.64	-5.61	-3.48	-3.54
epsdiluted	-0.69	-1.25	-1.71	-1.63	-0.99	-1.43	-0.64	-5.61	-3.48	-3.54
weightedAverageShsOut	67,493,000	80,232,000	92,135,000	102,335,000	115,684,000	122,207,000	131,257,000	151,137,000	171,348,000	176,351,000
weightedAverageShsOutDil	67,493,000	80,232,000	92,135,000	102,335,000	115,684,000	122,207,000	131,257,000	151,137,000	171,348,000	176,351,000
costAndExpenses	50,905,000	102,337,000	198,505,000	268,392,000	384,299,000	613,933,000	1,110,075,000	2,049,744,000	2,602,555,000	2,661,821,000
otherExpenses	--	1,600,000	4,100,000	--	107,597,000	--	16,035,000	69,733,000	95,001,000	110,694,000

Key Facts

Industry

Diagnostics & Research

Sector

Healthcare

Headquarters

Madison, WI, US

Website

exactsciences.com

CEO

Mr. Kevin T. Conroy

Employees

6300

About the Company

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.